Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kyverna Therapeutics Inc (KYTX)

Kyverna Therapeutics Inc (KYTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential

Biotech investors hunting for explosive growth may want to look closely at two emerging innovators making significant progress in high-impact therapeutic areas. Kyverna Therapeutics (KYTX) is advancing its breakthrough CAR T-cell programs in autoimmune diseases, while Janux Therapeutics (JANX) is using its cutting-edge TRACTr, TRACIr, and ARM platforms to alter tumor-activated immunotherapy. Both have earned “Strong Buy” ratings from analysts, with Wall Street forecasting extraordinary upside in 2026. 

Valued at $358.2 million, Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing CAR T-cell therapies for autoimmune diseases. Kyverna's flagship program, KYV-101, is moving quickly through late-stage development. It is a CD19 CAR...

Fundamentals

See More
  • Market Capitalization, $K 366,135
  • Shares Outstanding, K 43,796
  • Annual Sales, $ 0 K
  • Annual Income, $ -127,480 K
  • EBIT $ -172 M
  • EBITDA $ -169 M
  • 60-Month Beta 3.66
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.33

Options Overview Details

View History
  • Implied Volatility 141.56% (+36.20%)
  • Historical Volatility 104.10%
  • IV Percentile 17%
  • IV Rank 9.95%
  • IV High 1,176.69% on 03/20/25
  • IV Low 27.16% on 04/14/25
  • Expected Move (DTE 7) 0.26 (2.76%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 671
  • Volume Avg (30-Day) 158
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 4,184
  • Open Int (30-Day) 5,522
  • Expected Range 9.00 to 9.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.84
  • Number of Estimates 5
  • High Estimate -0.81
  • Low Estimate -0.88
  • Prior Year -0.88
  • Growth Rate Est. (year over year) +4.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.39 +45.62%
on 11/14/25
9.75 -4.56%
on 12/12/25
+1.98 (+26.94%)
since 11/12/25
3-Month
3.78 +146.16%
on 09/15/25
9.75 -4.56%
on 12/12/25
+5.39 (+137.37%)
since 09/12/25
52-Week
1.78 +422.75%
on 04/17/25
9.75 -4.56%
on 12/12/25
+4.85 (+108.63%)
since 12/12/24

Most Recent Stories

More News
2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential

These two biotech disruptors are poised for triple-digit breakout gains.

KYTX : 9.28 (+11.00%)
JANX : 15.23 (-0.85%)
$SPX : 6,827.05 (-1.07%)
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026 Positive...

KYTX : 9.28 (+11.00%)
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

EMERYVILLE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients...

KYTX : 9.28 (+11.00%)
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Initial funding of $25 million from the first of four tranches  Facility strengthens Kyverna’s financial flexibility, further supporting advancement of its late-stage indications in generalized...

KYTX : 9.28 (+11.00%)
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company’s registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically...

KYTX : 9.28 (+11.00%)
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstrate...

KYTX : 9.28 (+11.00%)
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

EMERYVILLE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune...

KYTX : 9.28 (+11.00%)
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS) KYV-101...

KYTX : 9.28 (+11.00%)
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Oral presentation to include topline efficacy and safety data for 6 patients with up to  9 months of follow up ​ Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to ...

KYTX : 9.28 (+11.00%)
Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome Innovative FDA-aligned KYSA-6 Phase...

KYTX : 9.28 (+11.00%)

Business Summary

Kyverna Therapeutics Inc. is a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company's lead product candidate includes KYV-101. Kyverna Therapeutics Inc. is based in EMERYVILLE, Calif.

See More

Key Turning Points

3rd Resistance Point 8.96
2nd Resistance Point 8.67
1st Resistance Point 8.51
Last Price 9.28
1st Support Level 8.06
2nd Support Level 7.77
3rd Support Level 7.61

See More

52-Week High 9.75
Last Price 9.28
Fibonacci 61.8% 6.71
Fibonacci 50% 5.76
Fibonacci 38.2% 4.82
52-Week Low 1.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar